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Abstract Angiotensin Converting Enzyme 2 (ACE2) is the human 
receptor that interacts with the Spike protein of coronaviruses, 
including the one that produced the 2020 coronavirus pandemic 
(COVID-19). Thus, ACE2 is a potential target for drugs that disrupt 
the interaction of human cells with SARS-CoV-2 to abolish infection. 
There is also interest on drugs that inhibit or activate ACE2, i.e. for 
cardiovascular disorders or colitis. Compounds binding at alternative 
sites could allosterically affect the interaction with Spike protein. We 
here review biochemical, chemical biology and structural information 
on ACE2, including the recent cryoEM structures of full length ACE2. 
We conclude that ACE2 is very dynamic and that allosteric drugs 
may be developed to target ACE2. At the time of the 2020 pandemic, 
we suggest that available ACE2 inhibitors or activators in advanced 
development should be tested for their ability to allosterically 
displace the interaction between ACE2 and the Spike protein.  
1. General Introduction 
The Angiotensin Converting Enzyme 2 (ACE2), first described 
with a role in the renin-angiotensin system [1], is now considered 
a regulator of cardiovascular physiology, dietary amino acid 
homeostasis, innate immunity and gut microbial ecology. It is 
also the receptor of the severe acute respiratory syndrome 
coronaviruses (SARS-CoVs), including SARS-CoV-2, 
responsible for the 2020 pandemic. A number of excellent 
reviews focusing on different aspects of ACE2 function and 
relevance in disease have been published [2-6]. An earlier review 
had a focus on biochemistry, including details on ACE2 
glycosylation, substrate specificity, requirement of pH and Cl- for 
activity [7]. Here we review the structural and biochemical 
information on ACE2, analyse its dynamics and allosteric 
properties, and assess the possibility of identifying small 




ACE2 is a transmembrane protein with an extracellular 
carboxypeptidase domain, located at the cell membrane in a 
variety of epithelial cells, including lung and airways, olfactory 
system, heart, kidneys, liver, pancreas and intestine [2, 8-9]. ACE1 
and ACE2 are coded by different genes and share a 40% amino 
acid sequence identity in the catalytic domain. While ACE1 
catalyses the formation of Angiotensin II (Angiotensin 1-8; 
DRVYIHPF) leading to vasoconstriction, increased blood 
pressure, cardiac hypertrophy and inflammation among other 
effects, ACE2 processes Angiotensin II to Angiotensin 1–7 
(DRVYIHP) and Angiotensin I to Angiotensin 1–9 (DRVYIHPFH), 
both enhancing vasodilatation and reducing blood pressure (Fig. 
1). Thus, ACE2 is protective in multiple cardiovascular diseases, 
such as hypertension and heart failure [10-11]. The difference at 
the active sites between ACE1 and ACE2 is such that ACE1 
inhibitors (i.e. enalapril, lisinopril, captopril) do not cross react 
with ACE2. ACE2 inhibitors have been developed, including 
MLN-4760 (also termed GL1001), DX-600, and 416F2 [12-14]. 
Inhibition of ACE2 with MLN-4760 showed beneficial effects on 
a model of colitis in mice [15] and entered clinical trials for the 
treatment of Ulcerative Colitis (www.clinicaltrials.gov). 
Figure 1. Simplified scheme on the role of ACE2 in the renin-angiotensin 
system. The cleavage of Angiotensinogen by the enzyme Renin results in the 
decapeptide Angiotensin I (1-10). Angiotensin Converting Enzyme 1 (ACE1) 
cleaves Angiotensin I to Angiotensin II (1-8). Angiotensin II is a potent 
vasoconstrictor that binds to the type 1 Angiotensin II Receptor (AT1R) to set 
off actions that result in higher blood pressure and inflammation. Angiotensin 
Converting Enzyme 2 (ACE2) cleaves Angiotensin II to produce Angiotensin 1-
7 which binds to Mas Receptor (MasR) producing vasodilation and other 
cardioprotective actions. ACE2 is cleaved by ADAM17 which releases the 
active ACE2 protease catalytic domain to the circulation. 
ACE2 is cleaved at the cell membrane by the ADAM17 protease 
(tumour necrosis alpha convertase, TACE) [16], and by other 
proteases such as TMPRSS2, HAT and hepsin [17-18]. The 
cleavage by ADAM17, in a process termed shedding, releases 
catalytically active soluble forms of ACE2 into the circulation, 
with a still unclear physiological function [19-20]. Recombinant 
human ACE2 18-740 (rhACE2; i.e. GSK2586881/APN01) is 
being tested in clinical trials for diverse disorders including lung 
injury and pulmonary arterial hypertension [21]. 
GSK2586881/APN01, and also B38-CAP, a bacterial-derived 
carboxypeptidase, which cleaves both Ang I and Ang II to Ang 
1–7 [22], are also in clinical trials for the treatment of SARS-CoV-
2 infections. 
ACE2 exerts indirect physiological functions on intestinal amino 
acid homeostasis, such as expression of antimicrobial peptides, 
and on the gut microbiome, by stabilizing the amino acid 
transporter B°AT1 with a chaperone-like mechanism [5, 23]. In 
animal models the expression of ACE2 is upregulated by 
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been replicated in humans [24]. ACE2 expression is enhanced by 
interferon IFNα in human airway epithelial cells [25]. 
1.2. ACE2 and the mechanism of SARS-CoV/CoV-2 infection 
SARS-CoV-2 mechanism of infection is similar to SARS-CoV-1 
(formerly known as SARS-CoV). The infection is mediated by a 
viral protein termed Spike, or S-protein, and ACE2 using a type I 
mechanism of fusion with target cells. [6, 26-34]. Although CD209L 
(L-SIGN) has been described as a co-receptor of SARS-CoV [35], 
the sole transfection of ACE2 into SARS-CoV-refractory cell 
lines confers susceptibility to infection [36]. The cleavage of ACE2 
is linked to the entry of SARS-CoV-1 into cells [17-18, 37]. 
TMPRSS2 also cleaves the Spike protein and primes it to allow 
viral entry into the cells [32]. Inhibition of TMPRSS2 by the 
clinically approved drug camostat mesylate inhibits viral infection 
[32, 38]. Therefore, cells throughout the body that express both 
proteins could be target of the coronavirus infection [9]. 
Altogether, there is plenty of evidence to sustain that ACE2 is 
the key receptor that enables infection of human cells by 
coronaviruses infecting humans like SARS-CoV-1 [6, 39], HCoV-
NL63 [40] and SARS-CoV-2 [32]. Therefore, pharmacological 
targeting of human ACE2 could lead to decreased interaction 
with the Spike protein from SARS-CoVs, inhibiting infectivity and 
becoming a means for the treatment of infected patients. 
Targeting human ACE2 instead of aiming the viral Spike protein 
directly has the benefit of being a more widely applicable 
treatment in the event of future strains or mutations of SARS-
CoVs.  
It is established that the Spike protein from SARS-CoVs 
attaches to ACE2 at a site different from the ACE2 peptidase 
active site [8]. Thus, it is not expected that ACE2 inhibitors that 
bind at the active site of ACE2 could directly compete with the 
Spike protein for the same interaction site. On the other hand, if 
ACE2 was allosteric, a drug binding at the active site, or to an 
alternative pocket, could affect the interaction of the Spike 
protein at the distant site allosterically and could be a possible 
approach for the treatment of COVID-19 patients. 
1.3. Allostery 
Allostery is a central mechanism that mediates cellular 
regulation. Allostery involves the structural and dynamic 
communication between at least two sites on a protein, site A 
and site B, in such a way that the occupancy of site A, will affect 
the conformation of site B, determining a physiological response 
[41-42]. Since allostery is bidirectional, the occupancy of site B can 
also affect the conformation of site A.  
Numerous allosteric drugs have been approved, the oldest being 
Benzodiazepines [43-44]. Over the last two decades, rational 
allosteric drugs have been developed to the G protein-coupled 
receptor family [45] including Maraviroc and Cinacalcet. Allosteric 
drugs such as Nevirapine [46] and Sofosbuvir [47] have also 
provided treatment options for human immunodeficiency virus 
and human hepatitis C virus infections. When compared to 
drugs binding at orthosteric sites, allosteric inhibitors can add 
the benefit of higher selectivity. Interestingly, as could be the 
case for ACE2, drugs directed to the orthosteric/active sites of 
enzymes can also produce effects on distant sites and 
allosterically enhance or disrupt interactions [48].  
Studies on allostery and drug development to allosteric proteins 
show that the allosteric effect is often not visible from the 
analysis of crystal structures. Molecular dynamic studies can 
predict if a small compound binding at a first site can induce 
rigidity or mobility at a second distant site; however, rigidity or 
mobility at a particular site does not directly relate to increase or 
decreased binding of interacting proteins [49].  
Specific studies on ACE2 dynamics and allostery have not been 
performed, although molecular dynamics simulations are 
presently being performed actively [50-51]. In the absence of 
specifically designed experimental studies, we can deduce 
dynamics and allostery from biochemical, chemical biology and 
structural work published over the years. 
2. Deduced dynamics and allostery from 
biochemical and structural studies on ACE2 
In the following paragraphs we summarize biochemical and 
structural knowledge on ACE2 that can inform about the 
possible existence of allostery and participation in an allosteric 
network. 
2.1. Biochemical studies 
ACE2 consists of a catalytic domain (Protease catalytic Domain, 
PD) and a Collectrin-like domain (CLD) that includes a neck 
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domain, a single transmembrane sequence and a cytoplasmic 
43 amino acid tail (Fig. 2A,B).  
The enzymatic activity of the PD can be inhibited by compounds 
or polypeptides binding to the substrate-binding site, i.e. MLN-
4760. MLN-4760 does not affect the interaction of ACE2 with the 
Spike protein of the SARS-CoV-1 in immunoprecipitation 
experiments nor does it affect the coronavirus infection of cells 
in culture [52]. MLN-4760´s potency is improved by increased 
chloride concentrations and mutagenesis analysis showed that 
Arg169 and Arg514 were critical to mediate the chloride-
dependent increase in the potency of MLN-4760 [53]. Interestingly, 
Arg169 of ACE2 is approximately at a 16 Å distance from MLN-
4760 binding site and so it is unlikely to directly affect inhibitor 
binding, but rather to allosterically affect the active site. 
Supporting this hypothesis, chloride was also shown to modulate 
substrate selectivity of ACE2 [54]. 
Is the ACE2 active site linked to other distant allosteric sites? 
While mutations of ACE2 at the active site render ACE2 inactive, 
the mutant protein still interacts with Spike protein and mediates 
infection, indicating that the catalytic activity of ACE2 is not 
required for SARS-CoV-1 interaction and infection [28]. The effect 
of Spike protein S1 domain on ACE2 enzymatic activity was 
tested using purified recombinant ACE2 and a peptide substrate 
that fluoresces upon cleavage (Mca-YVADAPK(Dnp)-OH 
substrate). Li et al. found that the Spike protein does not affect 
the in vitro activity of ACE2 [52]–although the data are not shown 
in the manuscript. This result provides evidence that at least 
some interactions at the Spike-binding site may not affect the 
catalytic activity of ACE2. The finding suggests that if there was 
an endogenous protein binding to the Spike-binding site of 
ACE2, or a treatment with exogenous Receptor Binding Domain 
(RBD) from the Spike protein itself, it could block the interaction 
of human cells with SARS-CoVs without affecting ACE2 catalytic 
activity and its physiological function in the regulation of the 
renin-angiotensin system. 
2.2. Structural and structure-based studies on the protease 
catalytic domain (PD) 
There are over 20 crystal and cryoEM structures of the PD 
deposited in the Protein Data Bank. Most structures of the 
isolated PD show the catalytic domain with the active site in an 
“open” conformation (i.e. PDB 1R4L, 6M17, 6M18, 6LZG). A 
closed conformation is observed only in complex with MLN-4760 
(PBD 1R42) [55] (Fig. 2C-D). There are also structures in an 
“intermediate” conformation, all of them in complex with the RBD 
of Spike from SARS-CoV-1 or a chimera of SARS-CoV-1 and 2 
(i.e. PDB 6ACK, 2AJF, 6VW1). Open and closed conformations 
vary at the active site and at the “back”, along the hinge region 
(shown as schemes in Figure 2C).  
 
Figure 2. Structure and 
Conformations of ACE2. (A) 
Scheme of motifs and domains of 
ACE2. ACE2 has an N-terminal 
Protease Catalytic Domain PD 
(blue) and a C-terminal Collectrin-
like-domain CLD (cyan). The first 17 
amino acids correspond to the 
signal peptide that is cleaved during 
the maturation of the protein (not 
shown). The CLD consists of an 
extracellular Neck Domain, a linker, 
a single transmembrane (TM) helix 
and an intracellular tail of 43 amino 
acids. The cleavage site by 
proteases that release soluble 
ACE2 to the circulation are indicated. 
(B) Structure of full length ACE2 
(tight-dimer) in complex with B°AT1 
(PDB: 6M17). ACE2 is represented 
as cylindrical helices and loops with 
surface, while the surface of B°AT1 
is presented in grey. For 
simplification, the RBDs present in 
this structure are not shown. The 
monomers of ACE2 are coloured in 
blue and pink shades (following the 
colours of A). The different regions 
of ACE2 and the 4 key regulatory 
sites (1. active site; 2. hinge; 3. 
Claw-like or Spike (RBD)-binding 
site; 4. PD dimerization interface) 
are indicated. (C) Schematic 
representation of the open-close 
hinge movement of the PD. The 
active site of the PD can adopt an 
open, intermediate (not shown) or 
closed conformation. The hinge 
pocket is disassembled in the 
closed structure. (D) MLN-4760 
binds at the active site, stabilizes 
the closed structure and does not 
affect the interaction with Spike. (E) 
Small compounds designed to bind 
at the hinge region, i.e. diminazene, 
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Small compound designed to bind at the active site in the closed structure of 
PD (NAAE) displaces interaction with Spike protein. (G) Schematic 
representation of the structure of full length ACE2 dimers in two conformations 
identified by cryoEM in complex with B°AT1. In the absence of the Spike 
protein RBD, the two conformations are found in a 3:1 proportion. The tight-
dimer (left) is a scheme representing the structure shown in B. In both dimer 
conformations the Neck domains form tight interactions. In the loose-dimer 
(right), the PDs rotate with respect to the Neck Domain and the PD-PD 
interaction is lost. In the presence of Spike protein RBD, only the tight-dimer 
ACE2 structure is present. In the loose-dimer the conformation of the Spike 
protein binding site in the PD appears modified (detailed in Figure 3). (H) 
Chemical structures: 1, XNT; 2, MLN-4760; 3, resorcinolnaphthalein; 4, NAAE; 
5, diminazene. The mechanisms of action for XNT, resorcinolnaphthalein, 
NAAE and diminazene (E) and (F) are deduced from biochemical work and 
not validated structurally. 
Activators of ACE2 could be beneficial as drugs for the 
treatment of diabetic nephropathy, heart failure, or hypertension 
[56]. The structures of the isolated protease catalytic domain in 
open and closed conformations were used to screen in silico for 
compounds that bind at sites different from the active site. In a 
first study, Hernandez Prada et al. identified two small 
compounds (XNT and resorcinolnaphthalein) binding at the 
hinge region (Fig. 2B,C) that in an in vitro ACE2 activity assay 
(Mca-YVADAPK(Dnp)-OH substrate) activated ACE2 1.8 and 
2.2 fold, respectively, with EC50 values (concentration to achieve 
50% enhancement of activity) of approximately 20 μM [57]. Using 
the same approach, diverse FDA-approved drugs were identified 
as low µM binders and the compound diminazene was 
described to activate ACE2 (EC50 8 µM), by modifying both Km 
and Vmax (Mca-YVADAPK(Dnp)-OH substrate) (Fig. 2E;H) [58]. 
Together, these studies suggest that there is an allosteric 
communication between the hinge region and the active site. 
There is also evidence for possible allostery between the active 
site and the Spike protein binding site. Huentelman et al. 
performed an in silico screening based on the closed 
conformation of ACE2 to identify new compounds binding to the 
active site and described that the molecule NAAE (N-(2-
aminoethyl)-1 aziridine-ethanamine) inhibits ACE2 activity (IC50 
50 µM) [59]. Treatment with this molecule inhibited SARS-CoV-1 
membrane fusion. The finding indicates an allosteric 
communication between the active site of ACE2 and its site of 
interaction with Spike protein from SARS-CoV-1 (shown 
schematically in Figure 2F), suggesting that drugs may be 
developed to bind at the active site and disrupt the interaction 
with the SARS-CoV-2 Spike protein [59] . 
2.3. Structural studies on full length ACE2 
The Spike protein is a trimer. Interestingly, recent work shows 
that a monomeric form of the PD (ACE2 18-640) binds efficiently 
to the isolated RBD from Spike, but does not significantly bind 
full length Spike trimers, while the PD (18-640)-Fc dimer can 
bind full length Spike trimers with reduced on-rate but also 
reduced off-rate [60]. CryoEM studies with SARS-CoV virions 
show that it binds to three soluble ACE2-Fc molecules [61]. .After 
interaction with ACE2, the Spike trimer undergoes 
conformational changes that promote membrane fusion. It is not 
yet known whether ACE2 must also undergo conformational 
changes to enable infection. The structure of full length ACE2 
was recently elucidated by cryoEM in a complex with the amino 
acid transporter B°AT1 [8] (Fig. 2B). It shows that ACE2 is a 
dimer, as previously described biochemically [61-62]. Dimers 
provide additional possibilities for cooperative-allosteric effects, 
although these have not been described in ACE2. In the full-
length solved structure, B°AT1 supports the formation of dimers 
by stabilizing the Neck Domain and the transmembrane helix of 
ACE2. This is in agreement with previous work showing that 
ACE2 constructs comprising the extracellular regions, Neck 
Domain and PD, are dimers. Dimers of ACE2 comprising PD 
fused to the Fc domain of antibodies, have also been employed 
in research [61-62].  
The cryoEM solved structure of full length ACE2 revealed the 
existence of two types of dimers: the authors describe them as 
“closed-dimer” and “open-dimer” [8]. To avoid confusion with the 
“open” and “closed” conformations of the PD, we will refer to 
them as tight-dimer and loose-dimer respectively (shown 
schematically in Figure 2G). In the tight-dimer conformation the 
dimerization interface consists of a strong interaction between 
the CLD Neck domain and a second interaction between the two 
PDs. Interestingly, when the authors investigated by cryoEM the 
structure of full length ACE2 in the presence of the RBD, they 
identified only the ACE2 tight-dimer in complex with RBD (in the 
presence of 10 mM leucine). In the loose-dimer conformation, 
there is a rotation between the CLD and the PD (Fig. 2G, 3A), 
which breaks the dimer interaction between the PDs and 
separates both domains about 25 Å. As a result, the PDs do not 
interact, while the dimer still remains stable, mediated by the 
interface within the Neck domain. More notably, the cryoEM 
structure of the full length ACE2 reveals that the PD can be 
stabilized in a new structural “twisted” conformation (Fig. 2G and 
Fig. 3B). In this new conformation, the PD claw-like surface 
shows changes which include the shifting of residues involved in 
the interaction with the RBD [8, 63], most notably at the α1 helix of 
ACE2, the main point of interaction with the viral protein (Fig. 2G 
and Fig. 3C). 
3. Analysis on ACE2 dynamics and allostery 
The structural information of ACE2 obtained by crystallography 
and cryoEM provide snapshots depicting conformations that 
ACE2 can stably achieve. Taken together with the biochemical 
studies, we propose a cartoon model of ACE2 with various key 
sites that appear dynamic (Fig. 2C-F). We identify four key sites 
on the PD, the carboxypeptidase active site (site 1, Fig. 2B,C), 
the hinge pocket (at the back of the active site (site 2, Fig. 3B,C) 
and the claw-like surface that interacts with the RBD within the 
S1 domain of the viral Spike protein (site 3, Fig. 2B,C). In 
addition, based on the cryoEM full length structure, we must also 
consider the existence of a dimerization interface(site 4, Fig. 2B, 
F). How are these sites related to each other? The proteolytic 
domain can be observed in “open”, “closed” and “intermediate” 
conformations (Fig. 2C). These conformations refer to the 
“opening” of the active site, where the hinge region participates 
in the movement. The only structure in “closed” conformation 
corresponds to the crystal bound to the ACE2 inhibitor MLN-
4760 (Fig. 2D). The finding that compounds binding at the hinge 
region, site 2, can modulate the protease activity, site 1, 
provides evidence that the two sites are allosterically connected 
(Fig. 2E). While MLN-4760 binding to the active site does not 
affect the binding of the Spike protein to ACE2 (Fig. 2F), NAAE 
designed to bind at the active site in the closed conformation, 
disrupted interaction with the Spike protein. Therefore, we must 
also consider that a subset of compounds binding at ACE2 
active site (site 1) could affect site 3 and enhance or inhibit 
interaction with the Spike protein. The finding of the twisted 
conformation of the PD in the full-length loose-dimer shows a 
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twisted conformation has a modified claw-like surface, which, if 
stabilized, could impair efficient binding to RBD from the Spike 
protein at the claw-like site (site 3) and inhibit interaction with 
SARS-CoVs. 
It called our attention that the association of the cytoplasmic tail 
of ACE2 with a ubiquitous calcium-binding protein, calmodulin, 
reduces the cleavage and release of its extracellular peptidase 
domain [64-65]. One simple explanation could be that the 
interaction at the cytoplasmic domain induces a direct stabilizing 
effect on the extracellular region of ACE2, avoiding the exposure 
of the cleavage site or inhibiting the interaction with the protease. 
Although other mechanisms could also explain the finding, it is 
tempting to speculate that there is an allosteric communication 
between the cytoplasmic tail of ACE2 and the extracellular 
domain that could physiologically signal in both directions. 
Independently of the mechanism, pharmacologically affecting 
the calmodulin binding to the intracellular tail would be expected 
to modulate the stability of the extracellular domain. 
Another hint of allostery between distinct sites on ACE2 comes 
from the apparent contradiction that while ACE2 inhibitors 
appear to be beneficial for colitis, the knock-out of ACE2 
produces colitis [5]. ACE2 ameliorates colitis indirectly by 
stabilizing the neutral amino acid transporter B°AT1 by a 
mechanism that does not require ACE2 catalytic activity [66]. One 
possibility to explain this contradiction is that the ACE2 inhibitors 
binding at the active site, like MLN-4760, could stabilize ACE2, 
which will also stabilize B°AT1 allosterically. Since B°AT1 
interacts with the Neck domain and the transmembrane helix of 
ACE2, a direct effect by MLN-4760 could imply an allosteric 
communication between the active site of the PD and the CLD of 
ACE2. Following on the known interaction between B°AT1 and 
ACE2 it was also recently suggested that the B°AT1 inhibitor 
Nimesulide, approved drug in some countries, could potentially 
affect the interaction with the Spike protein, allosterically [67]. 
3.1. The strengths and limitations of the analysis 
The main limitation is that the studies on ACE2 were not 
designed to investigate its dynamics and allostery. However, a 
strength is that there is consistent information suggesting that 
ACE2 is dynamic and possibly populated in equilibrium between 
different conformations depicted schematically in Figure 2. The 
in vitro biochemical characterization of small molecule 
“activators” comprises an important experimental evidence of 
allostery. However, Haber et al. indicated that, in their hands, 
the claimed small molecule “activators” did not affect the in vitro 
activity of ACE2 (using Mca-APK-Dnp as a substrate) [68]. It is 
possible that the results of both groups of researchers may be 
correct, but that the conditions of the assay by Haber et al. did 
not reveal an increase in activity. There are different reasons for 
such discrepancy. For example, an allosteric activator can act by 
affecting the Km; in such case, the concentration of substrate 
used could mask the activating effect; the different substrates 
should be well characterized before a study for possible allostery, 
particularly for the characterization of allosteric compounds 
when the readout is the activity. At any rate, the compounds 
claimed to activate ACE2 in vitro did produce the desired effect 
in vivo. Noteworthy, except for MLN-4760, a confirmation that 
the experimental compounds indeed bind at the expected sites 
is missing. 
We here broadly assume that the understandings obtained with 
SARS-CoV-1 would turn out to be indistinguishable from SARS-
CoV-2. Although several important aspects have been found to 
be identical, the specific studies on the interactions of ACE2 with 
the Spike proteins may vary, since the RBD of the SARS-CoV-2 
Spike protein has additional residues participating in the 
interaction and higher affinity to ACE2 [63]. Studies on ACE2 
identified that it is phosphorylated at residue 680, and that this 
phosphorylation stabilizes the protein avoiding degradation [69]. It 
is not known if the phosphorylation could affect any of the 
characteristics of the protein described biochemically, by 
crystallography or by cryoEM. Also we should keep in mind that 
many studies on ACE2 have employed ACE2 PD-Fc dimers, 
which may not mimic the physiological dynamics of ACE2 
dimers. 
Figure 3. The rotated and twisted conformation of the full length ACE2 
loose-dimer. The images are obtained by alignment of the tight-dimer (blue) 
and loose-dimer (red). (A) Rotation of the PD in relation to the CLD. The 
rotation is shown upon alignment of the CLD. (B) The structure of the PD in 
the rotated-twisted loose-dimer. The rotated PD is modified at the RBD-
binding site. The image is produced by alignment of PD. The top region –
which interacts with the RBD of the Spike protein– undergoes changes, 
particularly in the α1 helix. The zoom depicts the RBD-binding site of ACE2 
upon aligning the last C-terminal portion of the α1 helix. In the loose-dimer 
some of the helix α1 residues that interact with the Spike protein RBD move 
about 4,5 Å (measuring from the Cα). The table indicates the relative 
movement between the tight-dimer and loose-dimer of C of relevant residues 
that interact with the Spike protein RBD. 
A possibly important finding emerges from the recently 
described loose-dimers of ACE2. The loose-dimer structure is a 
stable structure in equilibrium with the tight-dimers that bind the 
RBD. The “twist” rotation observed in the PD on the full length 
loose-dimer leads to the breaking of the α1 helix comprising 
residues that directly participate in the interaction with the Spike 
protein (Q24, D30, K31, H34,Y41, Q42) (Fig. 3C). Although the 
structure of this dimeric conformation was solved to low 
resolution (4.5 Å), the modifications at the claw-like site are 
important and, if stabilized, could preclude high affinity binding to 
the viral Spike protein. However, if the α1 helix was flexible, the 
conformation could also enhance the interaction to the Spike 
protein. The cryoEM twisted structure with disrupted RBD 
binding site shows that the PD active site is not significantly 
different from other open structures. This could indeed indicate 
that the modifications at the RBD binding site may not affect the 
active site. However, further dedicated investigations are 
needed to understand the ACE2 dynamic system in detail to 
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4. Summary and Outlook 
Allostery is a central widespread mechanism in all life forms, 
once defined as “the second secret of life”. In summary, ACE2 
appears as a highly dynamic protein, where allostery has been 
demonstrated to different degrees between the active site (site 
1), the hinge region (site 2), the claw-like/Spike protein binding 
site (site 3), and the Cl- biding site. In addition, there are 
potential allosteric communications between the active site and 
the stability of the B°AT1, and between the intracellular tail and 
the cleavage of the extracellular domain releasing PD to the 
circulation. The twisted catalytic domain of ACE2 observed in 
the full length cryoEM structure hints to the existence of a 
structural communication between parts of the full length protein 
and the claw-like/Spike binding site, which may be exploited by 
drugs to allosterically inhibit the interaction with Spike protein. 
From the drug discovery perspective, the dynamic features of 
ACE2 and the knowledge accumulated throughout the years 
support the possibility that ACE2 conformation and function 
could be modulated by allosteric drugs. On the one hand, we 
suggest that further studies should confirm the allosteric nature 
of ACE2, the role in physiology and the potential for exploiting 
the allosteric properties for drug discovery. On the other hand, 
the small compounds identified in chemical biology or drug 
discovery projects will help to define more clearly the allosteric 
features of ACE2 and the possible exploitation for therapies. The 
screening of a small library of compounds using an AlphaLISA-
based interaction assay between ACE2 and the RBD domain of 
the Spike protein identified small compounds that displace the 
interaction [70]. Such kinds of assays can identify small 
compounds that bind to ACE2 with different mechanisms of 
action to displace the interaction with Spike. Notoriously, one 
validated “hit” compound that displaced the interaction in vitro 
was the enalapril (IC50 7.5 µM), a prodrug approved for the 
treatment of hypertension that is converted by de-esterification 
to enaprilat [70], which is a potent ACE1 inhibitor. Together with 
the discussions above, the finding further highlights the 
possibility that enalapril, at the high concentrations used, may 
cross-react with ACE2, binding at the active site and 
allosterically displacing the interaction with the coronavirus 
Spike protein as depicted in Fig. 2F. The identified approved 
drugs are active in vitro at too high concentrations for use as 
anti-virals, but could help to pave the way for future anti-SARS-
CoV-2 drugs. 
Given that ACE2 appears as a highly dynamic protein with a 
complex allosteric network between key sites, the development 
of compounds interacting at one side should ideally be tested for 
their effects on the different distant sites. For example, an 
activator compound that enhances ACE2 catalytic activity could 
have an effect on its ability to affect the interaction with the 
Spike protein, the stability of B°AT1, the ability to be cleaved by 
ADAM17 or the intracellular interaction with calmodulin. 
Still, a major question is whether high affinity small compounds 
and drugs will be able to bind distinct sites on ACE2 to modulate 
its activity and its interaction with SARS-CoVs. Additional 
remaining questions related to ACE2 dynamics abound. Does 
ACE2 dynamic equilibrium between conformations have a 
physiological function? Is there an endogenous ligand that binds 
to the Spike protein binding site on ACE2? Does the interaction 
of the Spike protein with ACE2 allosterically affect any other 
conformation-dependent function of ACE2, i.e. B°AT1 stability, 
shedding, or intracellular signalling? Does SARS-CoVs infection 
require ACE2 conformational changes and dynamics? Do ACE2 
polymorphisms [71] affect ACE2 dynamics and infection by 
SARS-CoVs?  
Finally, in relation to the current COVID-19 pandemic we 
encourage the evaluation of all available drugs and advanced 
compounds targeting ACE2 for their abilities to allosterically 
inhibit the interaction with the Spike protein and to inhibit the 
infectivity by SARS-CoV-2. 
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ACE2 is a membrane carboxypeptidase with an enzymatic role in the Renin-Angiotensin system and a chaperone-like function on 
intestinal amino acid intake. Moreover, ACE2 is the cellular receptor that enables interaction and infection by SARS-CoV-2, 
producing COVID-19. We here review biochemical, chemical biology and structural studies published on ACE2 with a focus on ACE 
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